Brian Wong

Brian is counsel in Goodwin’s Private Equity group and part of the firm’s Healthcare Private Equity practice. His practice is focused on representing a wide range of clients in the healthcare space on issues related to M&A, healthcare regulatory and compliance matters.

Brian supports a broad range of clients, including private equity firms, public and private strategic healthcare clients, biotech companies, wholesalers and distributors, pharmaceutical companies, medical device manufacturers, group purchasing organizations, healthcare IT/digital health vendors and all manner of stakeholders in the pharmaceutical supply chain pharmaceutical. He also provides advice to providers and professionals, including hospitals, health systems, ambulatory surgery centers, physicians and physician practice groups, retail, specialty and long-term care pharmacies, diagnostic imaging facilities, clinical laboratories, physical, speech and occupational therapists, and skilled nursing and assisted living facilities.

Brian regularly counsels clients on issues related to federal and state fraud, waste, and abuse laws, including the federal Anti-Kickback Statute, the Physician Self-Referral Law (the Stark Law) and the False Claims Act. With a deep understanding of the intricacies of federal and state healthcare regulations, his experience also covers the many laws and regulatory schemes governing healthcare businesses, including fee-splitting, corporate practice of medicine, licensure, accreditation and certification, healthcare privacy and data security, telehealth, and billing and reimbursement issues under Medicare, Medicaid, and commercial payors. Brian also guides clients through complex audits and investigations such as False Claims Act allegations and payor issues such as network terminations by PBMs. He also provides comprehensive counsel to clients navigating the complexities of the 340B Drug Pricing Program to ensure all entities in the supply chain, including manufacturers, wholesalers, covered entities and contract pharmacies, effectively manage their participation and are in compliance with the regulatory requirements of 340B. 

Brian’s representative experience includes:

• Counseled financial sponsors and strategic investors on complex federal and state healthcare regulatory issues impacting M&A transactions
• Healthcare regulatory counsel for acquisitions and dispositions for multi-specialty physician groups; retail, compounding, and specialty pharmacies; and home health and hospice providers 
• Counseled pharmaceutical manufacturers regarding fraud, waste and abuse issues, including issues related to sales and marketing arrangements, consulting agreements, and arrangements with healthcare professionals
• Advised providers, including hospitals, physician groups, pharmacies, and medical device companies on billing and claims issues, compliance programs and procedures, and implementing compliance testing and monitoring

Prior to joining Goodwin, Brian was counsel at Troutman Pepper Hamilton Sanders, a senior associate at Hogan Lovells, an associate at Troutman Pepper, and an associate at Brach Eichler.

• Co-Author, “Additional Disclosure Required: CMS Implements Substantial Changes to Reporting Skilled Nursing Facility Ownership Information,” Goodwin Client Alert, December 1, 2023
• Co-Author, “Cybersecurity Toolkit for Healthcare and Public Health Sector,” Goodwin Client Alert, November 21, 2023